Levodopa deuterated - Teva Pharmaceutical Industries

Drug Profile

Levodopa deuterated - Teva Pharmaceutical Industries

Alternative Names: Deuterium containing levodopa - Teva Pharmaceutical Industries; Deuterium substituted levodopa - Teva Pharmaceutical Industries; SD-1077

Latest Information Update: 17 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Imphar AG
  • Developer Teva Pharmaceutical Industries
  • Class Antiparkinsonians; Catecholamines; Organic deuterium compounds; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 05 May 2015 Auspex Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
  • 16 Mar 2015 Auspex Pharmaceuticals has patent protection for levodopa deuterated in USA and European Union (Auspex Pharmaceuticals 10-K, March 2015)
  • 12 Jan 2015 Auspex Pharmaceuticals acquires complete worldwide rights to SD 1077 from Imphar AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top